Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
Statistics in Medicine · 2025
DOI: 10.1002/sim.70275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Alessandra Serra und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Cambridge, MRC Biostatistics Unit, Cambridge, UK. Hauptthemen laut MEDLINE: Research Design, Biomarkers, Clinical Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Medical Research Council.
Abstract (Originalsprache)
Identifying and quantifying predictive biomarkers is a critical issue of Precision Medicine approaches and patient‐centric clinical development strategies. Early phase adaptive designs can improve trial efficiency by allowing for adaptations during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. At an early stage, the goal is not to precisely define the target population, but to not miss an efficacy signal that might be limited to a biomarker subgroup. In this work, we propose a one‐arm two‐stage early phase biomarker‐guided design in the setting of an oncology trial where at the time of the interim analysis, several decisions can be made regarding stopping the entire trial early or continuing to recruit patients from the full or a selected patient population. Via simulations, we show that, although the sample size is limited, the proposed design leads to better decision‐making compared to a classical design that does not consider an enrichment expansion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Cambridge, MRC Biostatistics Unit, Cambridge, UK.
- Department of Statistical Methodology, Saryga, France.
- Translational Statistics Department, Institut de Recherches Internationales Servier, Gif-sur-Yvette, France.
ORCID-Profile: Alessandra Serra
Förderung
- National Institute for Health and Care Research
- Medical Research Council
Zitieren
APA
Serra, A., Saint-Hilary, G., Guilleminot, S., Geronimi, J., & Mozgunov, P. (2025). Adaptive Biomarker‐Based Design for Early Phase Clinical Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70275
Vancouver
Serra A, Saint-Hilary G, Guilleminot S, Geronimi J, Mozgunov P. Adaptive Biomarker‐Based Design for Early Phase Clinical Trials. Statistics in Medicine. 2025. doi:10.1002/sim.70275
BibTeX
@article{Serra2025,
author = {Serra, Alessandra and Saint-Hilary, Gaëlle and Guilleminot, Sandrine and Geronimi, Julia and Mozgunov, Pavel},
title = {Adaptive Biomarker‐Based Design for Early Phase Clinical Trials},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70275}
}
EUVIMED